Literature DB >> 20231858

Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians.

E Gebeyehu1, E Engidawork, A Bijnsdorp, A Aminy, U Diczfalusy, E Aklillu.   

Abstract

The objectives of the this study were to assess the influence of CYP3A5 genotype and sex on the variability in total CYP3A activity and to compare 4β-hydroxycholesterol and omeprazole sulfoxidation as phenotypic markers for CYP3A activity in Ethiopians. Healthy subjects (n=150) were genotyped for CYP3A5*3, *6 and *7 using allele-specific PCR and Taqman genotyping assays. Plasma levels of 4β-hydroxycholesterol, 3 h post-dose omeprazole and omeprazole sulfone, were determined by gas chromatography-mass spectrometry and high performance liquid chromatography, respectively. The frequency of CYP3A5*1, *3, *6 and *7 was 20.5, 67.3, 12.2 and 0%, respectively. The mean plasma 4β-hydroxycholesterol level was 35.4 ng ml⁻¹. The mean 4β-hydroxycholesterol level (P=0.0001) and the 4β-hydroxycholesterol/cholesterol ratio (P=0.004) were higher in women than in men. CYP3A5 genotype significantly correlated with the plasma 4β-hydroxycholesterol concentration (P=0.003) and 4β-hydroxycholesterol/cholesterol ratio (P=0.0002). The omeprazole/omeprazole sulfone ratio was significantly correlated with 4β-hydroxycholesterol and 4β-hydroxycholesterol/cholesterol ratio in CYP3A5*0/*0 genotypes but not in individuals carrying the CYP3A5*1 allele. No correlation of omeprazole/omeprazole sulfone ratio with sex or CYP3A5 genotype was observed. A clear gene-dose effect implies plasma 4β-hydroxycholesterol level as a useful endogenous biomarker for total CYP3A activity (CYP3A5 plus CYP3A4) whereas the omeprazole/omeprazole sulfone ratio reflects mainly CYP3A4 activity. Sex and CYP3A5 genotype influence total CYP3A activity. Ethiopians display high total CYP3A activity and a unique distribution of CYP3A5 variant alleles not described hitherto.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20231858     DOI: 10.1038/tpj.2010.16

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  20 in total

Review 1.  Phenotyping of Human CYP450 Enzymes by Endobiotics: Current Knowledge and Methodological Approaches.

Authors:  Gaëlle Magliocco; Aurélien Thomas; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

Review 2.  Recommendations on the Development of a Bioanalytical Assay for 4β-Hydroxycholesterol, an Emerging Endogenous Biomarker of CYP3A Activity.

Authors:  Anne-Françoise Aubry; Brian Dean; Ulf Diczfalusy; Angela Goodenough; André Iffland; James McLeod; Naidong Weng; Ziping Yang
Journal:  AAPS J       Date:  2016-06-27       Impact factor: 4.009

3.  Cytochrome P450 3A activity in mothers and their neonates as determined by plasma 4β-hydroxycholesterol.

Authors:  Hanna Nylén; Sofia Sergel; Lisa Forsberg; Synnöve Lindemalm; Leif Bertilsson; Katarina Wide; Ulf Diczfalusy
Journal:  Eur J Clin Pharmacol       Date:  2011-01-19       Impact factor: 2.953

4.  4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients.

Authors:  Caroline Gjestad; Tore Haslemo; Ole A Andreassen; Espen Molden
Journal:  Br J Clin Pharmacol       Date:  2017-07-21       Impact factor: 4.335

5.  Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterol concentration.

Authors:  Kristine Hole; C Gjestad; K M Heitmann; T Haslemo; E Molden; S Bremer
Journal:  Eur J Clin Pharmacol       Date:  2016-12-14       Impact factor: 2.953

6.  High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population.

Authors:  Eleni Aklillu; Natasa Djordjevic; Juan Antonio Carrillo; Eyasu Makonnen; Leif Bertilsson; Magnus Ingelman-Sundberg
Journal:  OMICS       Date:  2013-12-31

Review 7.  4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans.

Authors:  Ulf Diczfalusy; Hanna Nylén; Pontus Elander; Leif Bertilsson
Journal:  Br J Clin Pharmacol       Date:  2011-02       Impact factor: 4.335

8.  Genome-Wide Association and Replication Study of Hepatotoxicity Induced by Antiretrovirals Alone or with Concomitant Anti-Tuberculosis Drugs.

Authors:  Zelalem Petros; Ming Ta Michael Lee; Atsushi Takahashi; Yanfei Zhang; Getnet Yimer; Abiy Habtewold; Ina Schuppe-Koistinen; Taisei Mushiroda; Eyasu Makonnen; Michiaki Kubo; Eleni Aklillu
Journal:  OMICS       Date:  2017-04

9.  Urinary 6β-Hydroxycortisol/Cortisol Ratio Most Highly Correlates With Midazolam Clearance Under Hepatic CYP3A Inhibition and Induction in Females: A Pharmacometabolomics Approach.

Authors:  Kwang-Hee Shin; Li Young Ahn; Man Ho Choi; Ju-Yeon Moon; Jieon Lee; In-Jin Jang; Kyung-Sang Yu; Joo-Youn Cho
Journal:  AAPS J       Date:  2016-06-17       Impact factor: 4.009

10.  Molecular diversity and population structure at the Cytochrome P450 3A5 gene in Africa.

Authors:  Ripudaman K Bains; Mirna Kovacevic; Christopher A Plaster; Ayele Tarekegn; Endashaw Bekele; Neil N Bradman; Mark G Thomas
Journal:  BMC Genet       Date:  2013-05-03       Impact factor: 2.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.